The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.
 
Manuel Hidalgo
No Relationships to Disclose
 
Igor Bazin
No Relationships to Disclose
 
Jean-Luc Canon
Consulting or Advisory Role - Amgen
 
Elena Poddubskaya
No Relationships to Disclose
 
Nebojsa Manojlovic
Consulting or Advisory Role - Roche
Speakers' Bureau - Merck; pharmaSuisse; Roche; Takeda
 
Michele Milella
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Dejan Radenkovic
No Relationships to Disclose
 
Chris Verslype
Consulting or Advisory Role - Bayer; Ipsen; Novartis
Research Funding - Bayer
 
Wei Guo
Employment - EMD Serono
Stock and Other Ownership Interests - AstraZeneca (I)
 
Lars Damstrup
Employment - Merck Serono
Travel, Accommodations, Expenses - Merck Serono
 
Pascal Hammel
Honoraria - Merck Serono
Consulting or Advisory Role - Merck Serono